



Instructions: Accurate interpretation and reporting of genetic results is contingent upon the reason for testing, clinical information, family history, and ancestry. To help provide the best possible service, supply the information requested below and **send paperwork with the specimen, or return by fax to Mayo Clinic Laboratories, Attn: Molecular Technologies Laboratory Genetic Counselors at 507-284-1759. Phone: 800-533-1710 / International clients: +1-507-266-5700 or email MLIINT@mayo.edu**

Patient Information

Patient Name (Last, First Middle)		Birth Date (mm-dd-yyyy)
Sex Assigned at Birth <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown <input type="checkbox"/> Choose not to disclose	Legal/Administrative Sex <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Nonbinary	

Referring Provider Information

Referring Provider Name (Last, First)	Phone	Fax*
Genetic Counselor Name (Last, First)	Phone	Fax*

*Fax number given must be from a fax machine that complies with applicable HIPAA regulations.

Is this a postmortem specimen? Yes No If "Yes," attach autopsy report if available.

Reason for Testing Specify below or attach relevant clinic note.

Confirm clinical diagnosis; specify diagnosis: _____ Age of onset: _____

Family history**, describe: _____

Other; specify: _____

**Genetic testing should be performed on an affected family member first, when available. FMTT / Familial Variant, Targeted Testing should be ordered when there is a previous positive genetic test result in the family.

Clinical Presentation

Epstein Barr Virus (EBV) susceptibility Familial hemophagocytic lymphohistiocytosis (F-HLH)

Other viral susceptibility; specify: _____ Other; specify: _____

Lymphoproliferative disorder

Clinical Features Check all that apply.

<input type="checkbox"/> Abnormal bleeding	<input type="checkbox"/> Fulminant viral hepatitis	<input type="checkbox"/> Pityriasis-like lesions
<input type="checkbox"/> Abnormal pigmentation	<input type="checkbox"/> Hemophagocytosis	<input type="checkbox"/> Severe influenza pneumonia
<input type="checkbox"/> Brainstem encephalitis	<input type="checkbox"/> Herpes simplex encephalitis	<input type="checkbox"/> Severe mononucleosis
<input type="checkbox"/> Critical COVID-19 pneumonia	<input type="checkbox"/> Hypogammaglobulinemia	<input type="checkbox"/> Splenomegaly
<input type="checkbox"/> Disseminated intravascular coagulation	<input type="checkbox"/> Live-attenuated viral vaccine strain disease	<input type="checkbox"/> Varicella zoster virus encephalitis and cerebellitis
<input type="checkbox"/> Epidermodysplasia verruciformis	<input type="checkbox"/> Lymphoproliferation	<input type="checkbox"/> Warts
<input type="checkbox"/> Fever	<input type="checkbox"/> Neurological symptoms	<input type="checkbox"/> Other; specify: _____

Oncologic History

Note: Skin biopsy is the preferred specimen type to detect germline variants in patients with active hematological malignancy.

<input type="checkbox"/> Myelodysplasia/AML	<input type="checkbox"/> Leukemia; specify: _____
<input type="checkbox"/> Lymphoma; specify: _____	<input type="checkbox"/> Skin cancer; specify: _____
<input type="checkbox"/> Solid tumor; specify: _____	<input type="checkbox"/> Other; specify: _____

Viral Susceptibility, Lymphoproliferation, and Hemophagocytic Lymphohistiocytosis

Patient Information (continued)

Patient Treatment History

Has the patient received an allogenic stem cell transplant***? No Yes; transplant date (mm-dd-yyyy): _____

Is the patient transfusion-dependent***? No Yes; last transfusion date (mm-dd-yyyy): _____
Was this transfusion leukoreduced***? No Yes Unknown

Chemotherapy: No Yes; date (mm-dd-yyyy): _____

***Results may be inaccurate due to the presence of donor DNA if the patient has received an allogeneic hematopoietic stem cell transplant or non-leukocyte reduced blood products. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.

General History

Anemia (Hemoglobin < 9 g/dL; neonates < 10 g/dL) Hyperferritinemia (≥ 500 mg/nL; ≥ 500 μ g/L)
 Thrombocytopenia (Platelets < 100×10^9 /L) Reduced or absent NK-cell cytotoxicity
 Neutropenia (Neutrophils < 1×10^9 /L) Elevated soluble CD25 (soluble IL-2 receptor)
 Hypertriglyceridemia (≥ 265 mg/dL; ≥ 3 mmol/L) Viral infection; specify: _____
 Hypofibrinogenemia (≤ 150 mg/dL; ≤ 1.5 g/L) Other infections; specify: _____

Family History

Are there similarly affected relatives? Yes No
If "Yes," indicate relationship, and diagnosis or symptoms: _____

Have any family members had genetic testing? Yes**** No Unknown

****FMTT / Familial Variant, Targeted Testing should be ordered when there is a previous positive genetic test result in the family. Contact the lab for ordering assistance.

History of consanguinity: No Yes; relationship details: _____

Ancestry

African/African American East Asian Latinx/Latine South Asian Unknown
 Ashkenazi Jewish European Middle Eastern None of the above Choose not to disclose

New York State patients: Informed Consent for Genetic Testing is required. See Informed Consent for Genetic Testing (T576), Informed Consent for Genetic Testing – Spanish (T826), or Informed Consent for Genetic Testing for Deceased Individuals (T782).